与免疫检查点抑制剂的免疫相关不良事件相关的喜剧药物
Léonard Laurent1, Baptiste Abbar2,3, Kevin Bihan4
1Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
Clinical pharmacology and therapeutics
|June 16, 2025
概括
在接受免疫检查点抑制剂 (ICI) 的患者中,某些非癌症药物增加了与免疫相关的不良事件 (irAE) 的风险. 这项研究确定了特定的药物组合,如质子抑制剂和NSAIDs与ICI,这些药物组合会提高irAE报告率.
科学领域:
- 药物监督 药物监督 药物监督
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 免疫检查点抑制剂 (ICI) 已经改变了癌症治疗,但可以引起与免疫相关的不良事件 (irAE).
- 喜乐药对IRAE发生的影响尚不清楚.
- 这项研究调查了ICI治疗的患者中药物治疗和irAE之间的关联.
研究的目的:
- 在接受ICI的患者中识别与增加irAE风险相关的辅助药物.
- 量化与特定药物相关的irAE的报告几率比率 (ROR).
- 探索某些药物和ICI之间的潜在协同毒性.
主要方法:
- 一项使用来自世卫组织Vigibase数据库的个体病例安全报告 (ICSR) 的药监测研究 (至2024年1月).
- 分析可疑或相互作用的药物,单独和按药物类 (解剖治疗化学品分类4级).
- 报告几率比率 (ROR) 的计算,以评估ICI接受者中药物和irAE之间的关联.
主要成果:
- 多种类型的药物与增加的irAE报告有关,包括质子抑制剂 (PPI) 和非类固醇抗炎药物 (NSAIDs) 在炎中.
- 类药物与肌肉炎有关,凯托可纳与肝炎有关,而二二乙酶-4抑制剂与自身免疫性斗牛性疾病有关.
- 严重的皮肤不良反应与PPI,某些抗感染药物,阿洛普林醇和 levetiracetam有关. 布洛芬和流感疫苗显示了与ICI的潜在协同毒性.
结论:
- 这项研究确定了与ICI治疗的患者具有更高特定irrAEs风险相关的几种辅助疗法.
- 一些已识别的药物组合可能表现出协同毒性,需要进一步调查.
- 研究结果强调了在接受ICI治疗的癌症患者中考虑使用康美治疗来治疗irrAEs的重要性.
相关概念视频
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Allergic Drug Reactions
1.0K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.0K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
490
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
490
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
267
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
267
Drugs Used in Lower Respiratory Disorders: Overview
635
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
635


